April 21

The Gardens at 780 Receives Haven Diagnostics Gold Verification

NUVEEN REAL ESTATE PLACES AN EMPHASIS ON PANDEMIC-PROOFING PREMIER NEW YORK OFFICE TOWER FOR OPTIMUM TENANT HEALTH



NEW YORK │April 1, 2021 Haven Diagnostics, a workplace health analytics company, today announced that they are in the process of awarding The Gardens at 780 in Midtown Manhattan a gold verification. Nuveen Real Estate, a leading global real estate manager, partnered with Haven Diagnostics to assist in the development plans to provide advanced commercial-level pandemic preparedness. Using Haven Diagnostics technology, Nuveen effectively addressed COVID-19 health and safety concerns resulting in a measured understanding of its space for its tenants.

The Gardens at 780


The Gardens, located on 3rd Avenue between 48th and 49th streets in the Plaza District of Midtown Manhattan, is undergoing a $40 million renovation that focuses on health and sustainability and will deliver in the first quarter of 2022. With Haven’s risk assessment, the development team can focus on communicating to its tenants the initiatives and strategic ventilation and filtration decisions made to ensure the tenants’ health and wellbeing. Features include increasing and renovating outdoor space as well as the double-height lobby, seven unique ingress/egress points for the lobby to reduce bottlenecks, and the installation of MERV-13 filters to improve air filtration. Other safety initiatives include slab to slab ceilings which result in a 9.0% local marginal risk reduction based on the property’s unique ventilation and filtration characteristics.

COVID-19 has put a spotlight on the importance of healthy workspaces. Haven Diagnostics uses its medical analytics software to create virtual twins of properties and help with data-driven decisions that lead to reduced risk in office environments. Making use of stress-tested ventilation, filtration and other public-health safety measures, the platform factors in building layout, tenant profiles, location, and HVAC. Haven Diagnostics' solution makes use of over 450 medical studies ensuring the latest scientific literature is incorporated into their models while also mitigating risk from future pandemics or public health crises.

“The Gardens is setting a gold standard for office redevelopment projects in New York,” stated Dr. Michael Gao, Medical Director for Haven Diagnostics. “Nuveen’s commitment to the ‘do-what-it-takes’ mentality to reduce infectious disease risk is paramount for its tenants and the future occupants at 780 Third.”

Created by Dr. Gao and Dr. Josh Geleris, Haven Diagnostics uses its proprietary agent-based modeling technology to create virtual twins of properties and simulate infectious disease as well as other health risks. This enables the company to guide in the design of more health-forward building decisions.

“We are always trying to understand how certain capital decisions impact our building's overall health risk, and with COVID-19, it is now at the forefront of every tenant’s mind,” said Brian Wallick, Director, New York Investments for Nuveen Real Estate. “Haven’s team was able to help us analyze each decision we contemplated and provided us with a quantified understanding of those respective decisions.''

The Gardens at 780 leads the way in the next chapter of the famed avenue’s redevelopment projects. A 520,000-square-foot office redevelopment, the building is creating a new standard for redevelopment in New York City which emphasizes health and wellbeing for its tenants.

For more information and media coverage please visit www.havendiagnostics.com or email ben@havendiagnostics.com.

#####

About Haven Diagnostics

Haven Diagnostics is a workplace analytics company giving employers and landlords infectious disease and health data for workplace needs. Founded in 2019, Haven’s software is deployed across 5 million square feet in North America and Europe.

The company is headquartered in New York City with an office in Dallas.

About Nuveen Real Estate

Nuveen Real Estate is one of the largest investment managers in the world with $133 billion of assets under management.

Managing a suite of funds and mandates, across both public and private investments, and spanning both debt and equity across diverse geographies and investment styles, we provide access to every aspect of real estate investing.

With over 80 years of real estate investing experience and more than 600 employees* located across over 25 cities throughout the United States, Europe and Asia Pacific, the platform offers unparalleled geographic reach, which is married with deep sector expertise.

For further information, please visit us at nuveen.com/realestate

*Includes 300+ real estate investment professionals, supported by a further 300+ Nuveen employees.

Source: Nuveen, 31 Dec 2020.


Media Contact:

Ben Siegel

Haven Diagnostics

212-381-6832

ben@havendiagnostics.com


Content Disclaimer: 

The above review statements are those of the sponsor (Source of content) and do not necessarily reflect the official policy, position or views of the content publisher. The content distribution company is therefore not responsible for the content and its authenticity and legal standing of the above subject matter. Each individual is required to exercise its content when making a purchase from the above offer. The information does not constitute advice or an offer to buy. Any purchase made from the above press release is made at your own risk. Editorial merit of this content is subject to news publisher and its downstream partners. Consult an expert advisor/health and professional advisor before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling as mentioned in the above as source. The content publisher and its downstream distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about.  

DISCLAIMER of Liability. IN NO EVENT SHALL OUR PR COMPANY BE LIABLE OR RESPONSIBLE TO YOU OR ANY OTHER PERSON FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, OR EXEMPLARY DAMAGES OF ANY KIND, INCLUDING WITHOUT LIMITATION, LOST PROFITS OR LOST OPPORTUNITIES, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES IN ADVANCE AND REGARDLESS OF THE CAUSE OF ACTION UPON WHICH ANY SUCH CLAIM IS BASED, INCLUDING, WITHOUT LIMITATION, ANY CLAIM ARISING OUT OF OR IN CONNECTION WITH ANY OF THE CONTENT, INCLUDING, WITHOUT LIMITATION, AUDIO, PHOTOGRAPHS, AND VIDEOS, OR OF THE ACCURACY, RELIABILITY, OR LEGALITY OF ANY STATEMENT MADE IN OR OMITTED FROM ANY advertisement, sponsorship, endorsement, testimonial, opinion, or other product-related or service-related statement or review appearing in the Websites or in ANY post or article distributed via the Websites.





Source: kisspr
Release ID: 17739